1. Home
  2. TNXP vs IIF Comparison

TNXP vs IIF Comparison

Compare TNXP & IIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$14.09

Market Cap

198.6M

Sector

Health Care

ML Signal

HOLD

Logo Morgan Stanley India Investment Fund Inc.

IIF

Morgan Stanley India Investment Fund Inc.

HOLD

Current Price

$21.33

Market Cap

202.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
IIF
Founded
2007
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
198.6M
202.8M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
TNXP
IIF
Price
$14.09
$21.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
366.4K
34.8K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
13.94%
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
N/A
Revenue This Year
$558.11
N/A
Revenue Next Year
$38.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$11.60
$19.83
52 Week High
$69.65
$28.37

Technical Indicators

Market Signals
Indicator
TNXP
IIF
Relative Strength Index (RSI) 51.94 40.85
Support Level $12.43 $19.83
Resistance Level $14.85 $22.66
Average True Range (ATR) 1.16 0.35
MACD 0.08 -0.08
Stochastic Oscillator 49.70 14.19

Price Performance

Historical Comparison
TNXP
IIF

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About IIF Morgan Stanley India Investment Fund Inc.

Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.

Share on Social Networks: